[1]王斯佳 王国兴.抗栓治疗后消化道出血的现状及抗栓策略[J].心血管病学进展,2020,(8):790-793.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
 WANG Sijia,WANG G uoxing.Current Characteristics and Anti-thrombotic Strategy of Gastrointestinal Hemorrhage after Anti-thrombotic Therapy[J].Advances in Cardiovascular Diseases,2020,(8):790-793.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
点击复制

抗栓治疗后消化道出血的现状及抗栓策略()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年8期
页码:
790-793
栏目:
综述
出版日期:
2020-08-25

文章信息/Info

Title:
Current Characteristics and Anti-thrombotic Strategy of Gastrointestinal Hemorrhage after Anti-thrombotic Therapy
作者:
王斯佳 王国兴
佳 王国兴 (首都医科大学附属北京友谊医院急诊科,北京100050)
Author(s):
WANG SijiaWANG G uoxing
(Department of Emergency,Beijing Friendship Hospital of Capital Medical College,Beijing 100050,China)
关键词:
抗栓治疗消化道出血现状防治策略
Keywords:
Anti-thrombotic therapy Gastrointestinal hemorrhage Current characteristics Treat strategy
DOI:
10.16806/j.cnki.issn.1004-3934.2020.08.002
摘要:
消化道出血是急诊常见的急危重症之一。近年来为了防治心脑血管疾病,口服抗血小板或抗凝药物的患者不断增多,使抗栓治疗后消化道出血的患者增加。现就抗栓治疗后消化道出血流行病学、临床预后及防治策略进行综述。
Abstract:
Gastrointestinal hemorrhage is one of common emergent clinical scenario.To prevent cardiovascular diseases,prescription of antiplatelet and anticoagulant therapy is significantly increased.And number of patients with gastrointestinal hemorrhage is subsequently increased.This literature is to review the epidemiology,prognosis and treat strategy of gastrointestinal hemorrhage after antiplatelet and anticoagulant therapy

参考文献/References:




[1] 抗栓治疗消化道损伤防治专家组.抗栓治疗消化道损伤防治中国专家建议(2016.北京)[J].中华内科杂志,2016,55(7):564-567.

[2] Sung JJ,Chiu PW,Chan FKL,et al.Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding:an update 2018[J].Gut,2018,67(10):1757-1768.

[3] Veitch AM,Vanbiervliet G,Gershlick AH,et al.Endoscopy in patients on antiplatelet or anticoagulant therapy,including direct oral anticoagulants:British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines[J].Gut,2016,65(3):374-389.

[4] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要 [J].中国循环杂志,2019,34(3):209-220.

[5] Mehran R,Rao SV,Bhatt DL,et al.Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium[J].Circulation,2011,123(23):2736-2747.

[6] Koskinas KC,Raber L,Zanchin T,et al.,Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions[J].Circ Cardiovasc Interv,2015,8(5):e002053 Epub.

[7] Raju N,Sobieraj-Teague M,Hirsh J,et al.Effect of aspirin on mortality in the primary prevention of cardiovascular disease[J].Am J Med,2011,124(7):621-629.

[8] Di Minno A,Spadarella G,Prisco D,et al.Antithrombotic drugs,patient characteristics,and gastrointestinal bleeding:Clinical translation and areas of research[J].Blood Rev,2015,29(5):335-343.

[9] Udell JA,Bonaca MP,Collet JP,et al.Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction:a collaborative meta-analysis of randomized trials[J].Eur Heart J,2016,37(4):390-399.

[10] Schelleman H,Brensinger CM,Bilker WB,et al.Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study[J].PLoS One,2011,6(6):e21447

[11] Ruff CT,Giugliano RP,Braunwald E,et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J].Lancet,2014,383(9921):955-962.

[12] Clemens A,Strack A,Noack H,et al.Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?[J].Ann Med,2014,46(8):672-678.

[13] Hallas J,Dall M,Andries A,et al.Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding:population based case-control study[J].BMJ,2006,333(7571):726.

[14] 华参,田海涛,朱晓法.心房颤动合并急性冠脉综合征患者抗栓治疗出血风险预测模型的研究进展[J].心血管病学进展,2018,39(1):30-36.

[15] Kikkert WJ,Delewi R,Ouweneel DM,et al.Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention:a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis[J].JACC Cardiovasc Interv,2014,7(6):622-630.

[16] Ostergaard K,Pottegard A,Hallas J,et al.Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death:a cohort study[J].Neuroepidemiology,2014,43(1):57-64.

[17] Sibon I,Orgogozo JM.Antiplatelet drug discontinuation is a risk factor for ischemic stroke[J].Neurology,2004,62(7):1187-1189.

[18] Weimar C,Cotton D,Sha N,et al.Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events:results from the PRoFESS study[J].Cerebrovasc Dis,2013,35(6):538-543.

[19] Rodriguez LA,Cea-Soriano L,Martin-Merino E,et al.Discontinuation of low dose aspirin and risk of myocardial infarction:case-control study in UK primary care[J].BMJ,2011,343:d4094.

[20] Derogar M,Sandblom G,Lundell L,et al.Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events[J].Clin Gastroenterol Hepatol,2013,11(1):38-42.

[21] Witt DM,Delate T,Garcia DA,et al.Risk of thromboembolism,recurrent hemorrhage,and death after warfarin therapy interruption for gastrointestinal tract bleeding[J].Arch Intern Med,2012,172(19):1484-1491.

[22] 窦丽稳,高伟波,朱继红.消化道出血后的抗栓治疗策略[J].中华急诊医学杂志,2019,28(2):147-150.

[23] Sung JJ,Lau JY,Ching JY,et al.Continuation of low-dose aspirin therapy in peptic ulcer bleeding:a randomized trial[J].Ann Intern Med,2010,152(1):1-9.

[24] Anderson JL,Adams CD,Antman EM,et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,61(23):e179-e347.

[25] Bhatt DL,Scheiman J,Abraham NS,et al.ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use:a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents[J].Circulation,2008,118(18):1894-1909.

[26] Cuisset T,Frere C,Quilici J,et al.Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study[J].J Am Coll Cardiol,2009,54(13):1149-1153.

[27] O’Donoghue ML,Braunwald E,Antman EM,et al.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials[J].Lancet,2009,374(9694):989-997.

[28] Kwok CS,Loke YK,.Meta-analysis:the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel[J].Aliment Pharmacol Ther,2010,31(8):810-823.

[29] Cardoso RN,Benjo AM,DiNicolantonio JJ,et al.Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors:an updated meta-analysis[J].Open Heart,2015,2(1):e000248.

[30] 孙寸杰,赵晖.血栓弹力图的临床应用进展[J].中华急诊医学杂志,2016,25(2):245-250.

相似文献/References:

[1]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
 LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[2]索妮 杨艳敏.心房颤动合并慢性冠状动脉综合征的抗栓治疗进展[J].心血管病学进展,2022,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
 SUO Ni,Y ANG Yanmin.Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(8):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
[3]张木馨 李丽英 阮海燕 何森.经导管主动脉瓣置换术后抗栓治疗进展[J].心血管病学进展,2022,(6):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
 ZHANG Muxin,LI Liying,RUAN Haiyan,et al.Progress of Antithrombotic Therapy after?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
[4]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
 DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(8):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[5]金冉阳 刘德敏 崔炜.经皮冠状动脉介入治疗围手术期抗栓治疗的演变[J].心血管病学进展,2023,(1):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
 JIN Ranyang,LIU Demin,CUI Wei.Evolution of Antithrombotic Therapy During Perioperative PCI[J].Advances in Cardiovascular Diseases,2023,(8):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]

备注/Memo

备注/Memo:

通讯作者:王国兴,E-mail:13520240749@163.com
收稿日期:2020-01-21

更新日期/Last Update: 2020-11-02